2seventy bio, Inc. (TSVT)

Market Cap	255.62M
Revenue (ttm)	37.86M
Net Income (ttm)	-57.25M
Shares Out	51.59M
EPS (ttm)	-1.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	489,659
Open	4.960
Previous Close	4.960
Day's Range	4.950 - 4.960
52-Week Range	2.290 - 5.990
Beta	1.74
Analysts	Buy
Price Target	7.60 (+53.38%)
Earnings Date	Mar 25, 2025

About TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 274
• Stock Exchange: NASDAQ
• Ticker Symbol: TSVT
• Website: https://www.2seventybio.com

Financial Performance

In 2024, 2seventy bio's revenue was $37.86 million, a decrease of -62.28% compared to the previous year's $100.39 million. Losses were -$57.25 million, -73.69% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for TSVT stock is "Buy." The 12-month stock price forecast is $7.6, which is an increase of 53.38% from the latest price.

Price Target

$7.6

(53.38% upside)

Analyst Consensus: Buy